GlassScriptPhysician profile
Zachary D Crees
NPI 1225419344
$27,391.25
in general payments reported to CMS, 2019-2025
16 companies · $17K in 2025
The $17K reported for 2025 was more than what 86% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $95.00 · 2021: $99.95 · 2022: $217 · 2023: $216 · 2024: $9,069 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Food and Beverage: $587 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $272 · Travel and Lodging: $271 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,522.50 |
| Food and Beverage | $586.99 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $271.74 |
| Travel and Lodging | $270.83 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gamida Cell INC. | $11,866.06 | 2024-2025 | Aphexda, Omisirge |
| Biolinerx USA, INC. | $9,000.00 | 2024 | Aphexda |
| Vertex Pharmaceuticals Incorporated | $4,767.00 | 2025 | |
| Taiho Oncology, INC. | $427.20 | 2025 | |
| Janssen Biotech, INC. | $210.90 | 2022-2023 | Talvey, Tecvayli, Carvykti |
| Astellas Pharma Global Development | $193.73 | 2025 | Xospata |
| Genentech USA, INC. | $184.79 | 2019-2023 | |
| Lilly USA, LLC | $166.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $115.37 | 2025 | |
| Incyte Corporation | $99.95 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.00 | 2022 | |
| Astellas Pharma US INC | $95.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $75.00 | 2025 | |
| Geron Corporation | $67.01 | 2025 | Rytelo |
| Celgene Corporation | $23.46 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Crees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.